🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  2. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  3. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  4. TAK-226

    Takeda

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  5. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  6. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  7. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  8. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  10. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  11. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  12. TAK-341

    Takeda

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  13. TAK-360

    Takeda

    Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  14. TAK-360

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  15. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  16. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  17. TAK-385

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  18. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

  19. TAK-442

    Takeda

    Acute Coronary Syndrome

    phase 2 small molecule completed

    1 trial

  20. TAK-442

    Takeda

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  21. TAK-448

    Takeda

    Low Testosterone

    phase 2 small molecule terminated

    1 trial

  22. TAK-448

    Takeda

    Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  23. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  24. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources